Compare Invesco DB Oil Fund (DBO) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs Quest Diagnostics Inc — how do they compare? Invesco DB Oil Fund trades at $20.91, while Quest Diagnostics Inc trades at $238.13 (market cap $26.21B). The key difference: Quest Diagnostics Inc pays a 1.45% dividend while Invesco DB Oil Fund pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals.
| DBO | DGX | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $23.80 | $238.50 |
52-Week Low | $11.98 | $173.49 |
Market Cap | — | $26.21B |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $20.88, up 0.14% today, with a bullish technical signal driven by moving averages and neutral oscillators. Recent news highlights oil market volatility due to Middle East supply disruptions and OPEC demand forecast cuts. The stock lacks disclosed financial ratios, limiting fundamental clarity amid sector-wide data reliability concerns.
Outlook hinges on oil price stability and company-specific updates, with upside potential from supply shocks but risks from demand weakness and geopolitical uncertainty. Investors await earnings and guidance for valuation anchors.
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
